2011;123:2434 506. S9.2.2-17. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997;278:212 6. S9.2.2-18. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hyper- tension in patients 80 years of age or older. N Engl J Med. 2008;358:1887 98. S9.2.2-19. Piller LB, Baraniuk S, Simpson LM, et al. Long-term follow-up of participants with heart failure in the antihypertensive and lipid-low- ering treatment to prevent heart attack trial (ALLHAT). Circulation. 2011;124:1811 8. S9.2.2-20. Davis BR, Kostis JB, Simpson LM, et al. Heart failure with pre- served and reduced left ventricular ejection fraction in the antihy- pertensive and lipid-lowering treatment to prevent heart attack trial. Circulation. 2008;118:2259 67. S9.2.2-21. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodies- terase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268 77. 9.3. Chronic Kidney Disease S9.3-1. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330:877 84. S9.3-2. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal dis- ease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939 46. S9.3-3. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pres- sure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421 31. S9.3-4. Upadhyay A, Earley A, Haynes SM, et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154:541 8. S9.3-5. 